ArticleFrontiers in allergy2024
Comparison of the new RIDA qLine Allergy multiparameter immunoblot and the ImmunoCAP Specific IgE test for the identification of clinically relevant food and aeroallergen allergies.
Article in Frontiers in allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiparameter immunoblot testing is increasingly used as an alternative to multiple individual IgE analyses for type 1 allergies. This study investigated the performance of an inexpensive immunoblot method, the RIDA qLine allergy test system (R-Biopharm AG), vs. the current gold standard. Methods: Three study-specific panels with 57 individual allergens (food and aeroallergens) were analyzed in serum samples from 200 patients with signs and symptoms of IgE-mediated allergies, using both the RIDA qLine Allergy and the reference method, the ImmunoCAP Specific IgE test (Thermo Fisher Scientific). In case of divergent results, corresponding allergens were remeasured using the secondary reference method, the 3gAllergy Specific IgE Universal Kit (Siemens). The clinical diagnoses of the 200 patients were included. In addition, a cross-reactive carbohydrate determinant (CCD)-inhibitor was used in the testing to decrease the incidence of positive CCD bands. Results: The mean overall agreement of all food and aeroallergens with the reference methods was 94.9%. Qualitative evaluation showed an average negative percent agreement of 98.9% and an average positive percent agreement of 75.1% for all individual allergens after testing with both reference methods. The additional treatment of samples with the CCD inhibitor successfully reduced the occurrence of positive CCD reactivity after retesting. Conclusion: The comparative analysis of RIDA qLine Allergy with the reference methods for specific IgE detection revealed a strong correlation between serum IgE levels measured across these platforms and clinical presentations, while also highlighting the necessity for careful contextual interpretation of results. Standardized allergen extracts would improve independent comparisons of different allergy testing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.